CDK4/6 inhibitors in breast cancer
Publication digest
View our publication digests to learn key findings on the use of CDK4/6 inhibitors for treatment of HR+/HER2−, node-positive, high-risk early breast cancer.
- Review data comparing clinical outcomes for various CDK4/6 inhibitors
- Learn the long-term benefits of adjuvant abemaciclib combined with endocrine therapy
- Consider the safety and tolerability profile of this combination therapy for breast cancer
Welcome:
Register to view statistics -
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event